Loteprednol | CAS#129260-79-3 | Antihyperlipidemic

MedKoo Cat#: 599258 | Name: Loteprednol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Loteprednol is an antihyperlipidemic agent.

Chemical Structure

Loteprednol

CAS#129260-79-3

Theoretical Analysis

MedKoo Cat#: 599258

Name: Loteprednol

CAS#: 129260-79-3

Chemical Formula: C21H27ClO5

Exact Mass: 394.1547

Molecular Weight: 394.89

Elemental Analysis: C, 63.87; H, 6.89; Cl, 8.98; O, 20.26

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Loteprednol;

IUPAC/Chemical Name

chloromethyl (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylate

InChi Key

YPZVAYHNBBHPTO-MXRBDKCISA-N

InChi Code

InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1

SMILES Code

O=C1C=C[C@]2(C)[C@@H]([C@@H](O)C[C@@]3([C@](C(OCCl)=O)(O)CC[C@@H]43)C)[C@H]4CCC2=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 394.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD, McDonald MB, Perry HD, Lane SS, Pflugfelder SC, Samudre SS. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014 Sep;40(5):289-96. doi: 10.1097/ICL.0000000000000049. PubMed PMID: 25083776. 2: Wu LQ, Chen X, Lou H, Cheng JW, Wei RL. Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis. Curr Med Res Opin. 2015 Aug;31(8):1509-18. doi: 10.1185/03007995.2015.1058250. PubMed PMID: 26039179. 3: Price MO, Feng MT, Scanameo A, Price FW Jr. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial. Cornea. 2015 Aug;34(8):853-8. doi: 10.1097/ICO.0000000000000475. PubMed PMID: 26020827. 4: Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013 Feb;39(2):168-73. doi: 10.1016/j.jcrs.2012.10.039. Epub 2012 Dec 8. PubMed PMID: 23232255. 5: Lyseng-Williamson KA. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery. Drugs. 2013 Jun;73(9):949-58. doi: 10.1007/s40265-013-0073-8. Review. PubMed PMID: 23740411. 6: Rajpal RK, Roel L, Siou-Mermet R, Erb T. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2013 Feb;39(2):158-67. doi: 10.1016/j.jcrs.2012.09.013. Epub 2012 Dec 3. PubMed PMID: 23218817. 7: Thanathanee O, Sriphon P, Anutarapongpan O, Athikulwongse R, Thongphiew P, Rangsin R, Suwan-apichon O. A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy. J Ocul Pharmacol Ther. 2015 Apr;31(3):165-8. doi: 10.1089/jop.2014.0107. Epub 2015 Jan 2. PubMed PMID: 25555173. 8: Lee H, Chung B, Kim KS, Seo KY, Choi BJ, Kim TI. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol. 2014 Dec;158(6):1172-1183.e1. doi: 10.1016/j.ajo.2014.08.015. Epub 2014 Aug 13. PubMed PMID: 25128594. 9: Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation. Cornea. 2015 Jul;34(7):725-32. doi: 10.1097/ICO.0000000000000436. PubMed PMID: 25850708. 10: Glogowski S, Lowe E, Siou-Mermet R, Ong T, Richardson M. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%. J Ocul Pharmacol Ther. 2014 Feb;30(1):66-73. doi: 10.1089/jop.2013.0142. Epub 2013 Dec 10. PubMed PMID: 24325539. 11: Beyazyıldız E, Acar U, Beyazyıldız Ö, Pınarlı FA, Albayrak A, Uğurlu N, Tiryaki M, Delibaşi T. Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats. J Ocul Pharmacol Ther. 2014 May;30(4):306-12. doi: 10.1089/jop.2013.0129. Epub 2014 Feb 4. PubMed PMID: 24494746. 12: Han YK, Segall AI. A validated specific stability-indicating RP-HPLC assay method for the determination of loteprednol etabonate in eye drops. J Chromatogr Sci. 2015 May-Jun;53(5):761-6. doi: 10.1093/chromsci/bmu121. Epub 2014 Sep 18. PubMed PMID: 25234383. 13: Rajpal RK, Fong R, Comstock TL. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Adv Ther. 2013 Oct;30(10):907-23. doi: 10.1007/s12325-013-0059-7. Epub 2013 Oct 18. PubMed PMID: 24136301. 14: Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012 Oct;32(5):507-17. Epub 2012 Jun 16. Review. PubMed PMID: 22707339; PubMed Central PMCID: PMC3459083. 15: Nasr FH, Khoee S. Design, characterization and in vitro evaluation of novel shell crosslinked poly(butylene adipate)-co-N-succinyl chitosan nanogels containing loteprednol etabonate: A new system for therapeutic effect enhancement via controlled drug delivery. Eur J Med Chem. 2015 Sep 18;102:132-42. doi: 10.1016/j.ejmech.2015.07.045. Epub 2015 Aug 1. PubMed PMID: 26263245. 16: Schopf L, Enlow E, Popov A, Bourassa J, Chen H. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation. Ophthalmol Ther. 2014 Dec;3(1-2):63-72. doi: 10.1007/s40123-014-0021-z. Epub 2014 Feb 4. PubMed PMID: 25134493; PubMed Central PMCID: PMC4254862. 17: Rajpal RK, Digby D, D'Aversa G, Mah F, Hollander DA, Conway T. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review. J Ocul Pharmacol Ther. 2011 Jun;27(3):305-8. doi: 10.1089/jop.2010.0182. Epub 2011 May 16. PubMed PMID: 21574815. 18: Pirouzian A, Craven ER. Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery. Clin Ophthalmol. 2014 Feb 10;8:379-87. doi: 10.2147/OPTH.S30278. eCollection 2014. Review. PubMed PMID: 24550666; PubMed Central PMCID: PMC3926497. 19: Wan PX, Wang XR, Song YY, Li ZY, Duan HC, Zhang W, Liu Z, Wang ZC. [Study on the treatment of dry eye with Loteprednol Etabonate]. Zhonghua Yan Ke Za Zhi. 2012 Feb;48(2):142-7. Chinese. PubMed PMID: 22490950. 20: Comstock TL, Paterno MR, Bateman KM, Decory HH, Gearinger M. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatr Drugs. 2012 Apr 1;14(2):119-30. doi: 10.2165/11596320-000000000-00000. PubMed PMID: 22292487.